vitro. Investigation of the SAR reveals that a sterically unhindered hydrogen bond acceptor attached to C-17 is most likely key to the enhanced activity. Compound 8 displayed significant in vitro antiangiogenic activity, and its ability to act as a microtubule disruptor was confirmed. Inhibitory activity of the sulfamate derivatives against steroid sulfatase and carbonic anhydrase II (hCAII) was also
                                    讨论了17-
氰基2-取代的estra-1,3,5(10)-
三烯作为抗癌剂的合成,
SAR和临床前评价。2-甲氧基17β-
氰基甲基estra-1,3,5(10)-
三烯-3-醇(14),但没有相关的2-乙基衍
生物7和相关的3-O-
氨基磺酸盐8和15显示出有效的抗增殖作用(分别针对MCF-7 GI 50 300、60和70 nM)对人癌细胞的抗癌作用。对
SAR的研究表明,连接C-17的空间不受阻碍的氢键受体很可能是增强活性的关键。化合物8显示出显着的体外抗血管生成活性,并证实了其充当微管破坏剂的能力。还观察到
氨基磺酸酯衍
生物对甾族
硫酸酯酶和
碳酸酐酶II(hCAII)的抑制活性,并通过蛋白质晶体学研究了15与hCAII之间的相互作用。在体内证实了这些多机制抗癌药的潜力,在无胸腺裸鼠
MDA-MB-231人乳腺癌异种移植模型中观察到有前景的14和15活性。